Protective effects of shikimic acid against thioacetamide-induced hepatic fibrosis: role of Nrf2/NF-κB signaling pathways
Frontiers in Pharmacology · 30.05.2025 · 16
DOI: 10.3389/fphar.2025.1609711 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 30.05.2025. Verfasst von Ashraf Albrakati. Beteiligte Einrichtung: Department of Anatomy, College of Medicine, Taif University, Taif, Saudi Arabia. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Liver fibrosis is a chronic condition marked by scar tissue accumulation in the liver that impairs function. Shikimic acid (SA) has demonstrated significant antioxidant and anti-inflammatory properties and is a hydroaromatic natural product found in various plant sources, including star anise. Thioacetamide (TAA) is commonly used as an experimental model to induce liver fibrosis. This study was designed to investigate the protective effects of SA against TAA-induced liver fibrosis in rats.
Methods
Fifty male Wistar rats were divided into five groups (n = 10): control, TAA (200 mg/kg), SA (50 mg/kg), and two combination groups receiving TAA plus SA (50 and 100 mg/kg). Treatments were administered intraperitoneally for 6 weeks. Liver function, oxidative stress markers, inflammatory mediators, apoptotic proteins, fibrogenic factors, and histopathology were assessed.
Results
SA treatment significantly attenuated liver fibrosis induced by TAA through improved liver enzymes, including alkaline phosphatase (ALP) and aspartate transaminase (AST), serum alanine transaminase (ALT) and antioxidant parameters, including catalase (CAT), glutathione peroxidase (GPx), glutathione reductase (GR), and superoxide dismutase (SOD). SA-enhanced nuclear factor erythroid 2-related factor-2 (Nrf2) expression while reducing oxidative stress markers, including nitric oxide (NO), malondialdehyde (MDA) and reduced glutathione (GSH), and inflammatory mediators, including tumour necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β) and nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB). Furthermore, SA demonstrated anti-apoptotic effects by modulating Bax, Bcl2, and caspase-3 levels and exhibited anti-fibrotic properties through suppression of transforming growth factor beta (TGF-β) and collagen type I alpha-1 chain (COL1A1) expressions. Notably, SA improved histopathological alterations with a slight presence of fibroplasia. These protective effects were more pronounced at the higher dose (100 mg/kg).
Conclusion
SA effectively protected against TAA-induced liver fibrosis through multiple mechanisms, including the normalisation of liver enzymes, enhancement of antioxidant defences via Nrf2 activation, suppression of inflammatory mediators, and modulation of apoptotic and fibrogenic pathways.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Anatomy, College of Medicine, Taif University, Taif, Saudi Arabia.
Zitieren
APA
Albrakati, A. (2025). Protective effects of shikimic acid against thioacetamide-induced hepatic fibrosis: role of Nrf2/NF-κB signaling pathways. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1609711
Vancouver
Albrakati A. Protective effects of shikimic acid against thioacetamide-induced hepatic fibrosis: role of Nrf2/NF-κB signaling pathways. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1609711
BibTeX
@article{Albrakati2025,
author = {Albrakati, Ashraf},
title = {Protective effects of shikimic acid against thioacetamide-induced hepatic fibrosis: role of Nrf2/NF-κB signaling pathways},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1609711}
}
EUVIMED